Get alerts for new trials in your area by subscribing now
Chronic kidney disease, or CKD, means the kidneys have been damaged and filter blood less well for three months or more. It is measured with two tests: eGFR, an estimate of filtering capacity calculated from blood creatinine, and a urine test for albumin, a protein that leaks when the kidneys are injured. Diabetes and high blood pressure cause about two thirds of kidney failure in the US; inflammatory kidney diseases such as glomerulonephritis and lupus nephritis, inherited conditions, and long term use of certain medicines cause most of the rest. Early CKD has no symptoms; later it causes swelling, tiredness, changes in urination, and nausea.
Treatment aims to slow the decline: controlling blood pressure and blood sugar, and medicines that protect the kidneys directly, including SGLT2 inhibitors, finerenone for kidney disease with type 2 diabetes, and semaglutide, approved in 2025 for people with diabetes and CKD. When the kidneys fail, options are dialysis or a transplant.
Our guide explains the stages of CKD and treatment options.
Kidney protecting drug trials. Large outcome trials of medicines that slow eGFR decline and prevent kidney failure, often in people with diabetes or high blood pressure.
Trials for specific kidney diseases. Targeted treatments for IgA nephropathy, FSGS, lupus nephritis, polycystic kidney disease, and other diagnoses made by biopsy or genetics.
Anemia and complication trials. Treatments for the anemia, bone and mineral problems, and heart disease that come with CKD; see anemia clinical trials.
Dialysis and transplant trials. Better dialysis schedules, access devices, and ways to keep transplanted kidneys healthy.
Kidney function studies for new medicines. Short studies that measure how a medicine behaves in people with reduced kidney function, which drug developers run for most new drugs.
Screening and early detection. Programs that find undiagnosed CKD in people with diabetes or high blood pressure.
New to research? Read how informed consent works.
Most drug trials enroll adults with CKD confirmed by eGFR in a set range, often between 20 and 60, and usually with albumin in the urine above a threshold, since that marks people whose disease is likely to progress. Many require a stable dose of a blood pressure medicine from the ACE inhibitor or ARB family, and trials for diabetic kidney disease require type 2 diabetes. Trials for specific kidney diseases require a biopsy or genetic diagnosis. Kidney function studies for new medicines enroll people with mild, moderate, or severe reduction in eGFR who are otherwise stable, and dialysis and transplant trials enroll those populations specifically. Eligibility always varies by study.
Interested in learning more about Farxiga? Read our guide: Farxiga Side Effects: Common, Serious, and What to Watch For
Stages 1 and 2 (eGFR 60 and above with kidney damage). Normal or mildly reduced filtering with protein in the urine; screening and early treatment trials.
Stage 3 (eGFR 30 to 59). Moderately reduced; the stage where most people are diagnosed and where most kidney protecting drug trials enroll.
Stage 4 (eGFR 15 to 29). Severely reduced; trials of treatments to delay dialysis and prepare for it.
Stage 5 (eGFR below 15). Kidney failure; dialysis and transplant trials.
Some studies offer compensation for time and travel, and study related care is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.
Curious whether clinical trials pay participants? Here's how compensation actually works.
Identify your trial. Use the filters and match the eGFR range and cause of kidney disease named in the study to your own results.
Select your preferred location. Enter your city or state; large outcome trials run at nephrology and primary care sites across the country.
Explore study details. Click "Learn More" for the eGFR and urine albumin ranges required, diabetes status, and current medicine rules.
Complete the health profile. Click "Get started" to begin the 5-step application. Have ready your most recent eGFR and urine albumin results, the cause of your kidney disease if known, and your blood pressure and diabetes medicines.
Submit the application. A clinical trial coordinator reviews it and contacts you. Nothing is decided until informed consent, and participation is voluntary at every step.